Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its LUCID-MS therapeutic candidate for multiple sclerosis (MS) after completing phase 1 clinical studies in healthy volunteers. The company reported that the therapy demonstrated a favorable safety profile and was generally well tolerated, marking a critical step toward addressing the unmet need for treatments that directly protect or restore myelin integrity.
Multiple sclerosis is a chronic autoimmune and neurodegenerative disease that affects more than 2.8 million people worldwide, including approximately 1 million in the United States. The condition occurs when the immune system attacks myelin, the protective sheath surrounding nerve fibers in the brain and spinal cord. As myelin deteriorates, communication between nerves becomes disrupted, leading to symptoms that can include loss of mobility and control of the body. Despite the availability of numerous immune-modulating therapies, many patients continue to experience worsening disability because current treatments often focus on reducing inflammation and relapse frequency without adequately addressing the underlying neurodegeneration and myelin damage that drive long-term disease progression.
Quantum BioPharma’s LUCID-MS program is built around this unmet need. The company reached a significant milestone in April 2026 when it announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for LUCID-MS. The IND submission follows the completion of phase 1 studies and positions the company to initiate phase 2 trials, pending FDA clearance.
The LUCID-MS candidate is a patented therapeutic designed to target demyelination and provide neuroprotection. According to the company, the therapy aims to slow or halt disease progression by preserving myelin integrity and protecting nerve cells from further damage. If successful, LUCID-MS could offer a new treatment paradigm for patients who have limited options beyond symptomatic management and immune modulation.
The announcement underscores the importance of developing therapies that directly address myelin repair. Current MS treatments, while effective at reducing relapses, do not reverse existing damage or prevent long-term disability. By focusing on neuroprotection, LUCID-MS may fill a critical gap in the MS treatment landscape.
Quantum BioPharma continues to advance its pipeline, with the latest news and updates available in the company’s newsroom at https://ibn.fm/QNTM. For more information about BioMedWire, visit https://www.BioMedWire.com.
